Fukuoka University

Other

National Institute of Radiological Sciences

Jiro Takata

Kazuhisa Matsunaga

Michihiro Fujiwara

Kenichi Mishima

Yoshiharu Karube

Shizuko Kobayashi

Katsunori Iwasaki

Kazuhiro Imai

Akihiro Hattori

Takeshi Fukushima

Megumi Ueno

Kazunori Anzai

Manabu Nakashima

Ryoji Hidaka

Nobuo Ikota

Makoto Akashi

Junichi Ueda

Haruko Yakumaru

Administration of either a tocopherol represented by the general formula (1) or a tocotrienol compound ester derivative before or after exposure to radiation is effective in preventing or treating health disorders caused by the radiation exposure. 

Radiation protection drug containing tocopherol or tocotrienol compound ester derivative as active ingredient

It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and/or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

Inhibitor of ischemic disorders

Tocotrienol derivative, process for producing the same and &ggr;-CEHC delivering agent

Growing community of inventors

Fukuoka, Japan

Jiro Takata